IPO Market Unlocking for 'Omics-related Companies, but It's 'Anything but Robust'

In addition to a challenging IPO market, experts said that private equity funding remains a challenge.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.